January 27th 2023
Vial will be supporting RecensMedical with the phase 3 clinical trial for its Ocu-Cool system.
Targeting VEGF: The future is now
November 17th 2022Ophthalmologists have learned to optimize their use of traditional anti-VEGF therapies and are now incorporating newer therapies like brolucizumab for managing retinal diseases, and in the not-so-distant future they can look forward to gaining familiarity with faricimab and using a new delivery system for ranibizumab.
Read More
Viatris making ophthalmology push with acquisition of Oyster Point Pharma
November 7th 2022Viatris intends to acquire Oyster Point Pharma as the foundation of its new ophthalmology franchise, recognizing its uniquely talented team, the strength of Tyrvaya nasal spray and its ophthalmology pipeline.
Read More
EYP-1901: A look at DAVIO and PAVIA clinical trial updates
November 3rd 2022Jay S. Duker, MD, chief operating officer of EyePoint Pharmaceuticals, highlights the Phase 1 and Phase 2 DAVIO clinical trials for EYP-1901 in wet age-related macular degeneration. The company also announced the first patient has been dosed in the Phase 2 PAVIA trial of EYP-1901 for nonproliferative diabetic retinopathy.
Read More
Aflibercept shown to work at higher dose, longer intervals
September 8th 2022Regeneron announced that the primary endpoints were met in two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens in patients with diabetic macular edema and wet age-related macular degeneration.
Read More
Two-year data confirms faricimab improves vision for patients diagnosed with wet-AMD
July 14th 2022In the TENAYA and LUCERNE studies, more than 60% of faricimab patients could be treated every 4 months at 2 years, an increase from 45% at year 1. Study results are being presented at the American Society of Retina Specialists 2022 annual meeting in New York.
Read More
Dry eye disease associated with Sjögren’s syndrome: Cost of treatment a factor
May 17th 2022In a paper, investigators identified strategies used by patients to reduce the cost of therapy and its impact on adherence to treatment Patients may be reluctant to disclose challenges regarding adherence to dry eye disease therapy, as well as fears of worsening quality of life.
Read More
Allergan announces positive topline Phase 3 results for presbyopia therapeutic
April 5th 2022According to the company, the VIRGO trial evaluated the safety and efficacy of the investigational twice-daily administration of pilocarpine HCl ophthalmic solution 1.25% in adults with presbyopia. The trial met its primary efficacy endpoint, the company noted.
Read More